Information Provided By: 
Fly News Breaks for October 6, 2015
ALDR
Oct 6, 2015 | 07:55 EDT
Leerink analyst Joseph Schwartz views the recent pullback in shares of Alder Biopharmaceuticals as an attractive buying opportunity. Two upcoming catalysts could derisk development of ALD403 for migraine prophylaxis, Schwartz tells investors in a research note. He expects multiple-dose Phase 1 capsaicininduced vasodilation data in healthy volunteers before year-end and Phase 2b chronic migraine data in early 2016. The analyst reiterates an Outperform rating on the stock with a $62 price target.
News For ALDR From the Last 2 Days
There are no results for your query ALDR
